金河生物
(002688)
| 流通市值：49.84亿 | | | 总市值：51.62亿 |
| 流通股本：7.45亿 | | | 总股本：7.72亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 625,145,364.48 | 2,370,626,965.11 | 1,657,273,697.64 | 1,065,746,197.18 |
| 营业收入 | 625,145,364.48 | 2,370,626,965.11 | 1,657,273,697.64 | 1,065,746,197.18 |
| 二、营业总成本 | 569,770,727.13 | 2,178,879,190.03 | 1,530,578,504.1 | 964,395,552.61 |
| 营业成本 | 401,461,943.22 | 1,576,257,210.52 | 1,105,938,899.22 | 710,820,314.38 |
| 税金及附加 | 5,882,721.31 | 17,602,452.63 | 12,101,915.29 | 7,757,666.28 |
| 销售费用 | 41,676,064.18 | 138,303,486.84 | 99,721,319.65 | 65,296,235.34 |
| 管理费用 | 77,746,262.18 | 285,819,440.74 | 197,806,033.33 | 113,141,216.28 |
| 研发费用 | 22,598,102.58 | 94,002,290.67 | 56,656,746.61 | 37,152,241.46 |
| 财务费用 | 20,405,633.66 | 66,894,308.63 | 58,353,590 | 30,227,878.87 |
| 其中:利息费用 | 22,075,500.85 | 80,335,510.72 | 57,420,653.68 | 38,016,127.38 |
| 其中:利息收入 | 1,128,705.2 | 6,896,094.14 | 4,704,772.3 | 3,265,549.19 |
| 加:公允价值变动收益 | -28,413.75 | 45,462 | 77,664.25 | 41,673.5 |
| 加:投资收益 | 87,375 | -1,269,364.34 | -631,039.01 | -631,039.01 |
| 资产处置收益 | - | 194,370.44 | 13,381.3 | 13,958.62 |
| 资产减值损失(新) | 572,214.29 | -82,022,808.9 | -17,338,597.73 | -11,141,250.13 |
| 信用减值损失(新) | -260,381.07 | -40,164,106.01 | -3,572,694.97 | -1,838,634.9 |
| 其他收益 | 3,864,033.64 | 30,020,094.32 | 20,099,005.62 | 13,188,026.46 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 59,609,465.46 | 98,551,422.59 | 125,342,913 | 100,983,379.11 |
| 加:营业外收入 | 7,428.37 | 1,565,075.41 | 325,635.63 | 250,718.14 |
| 减:营业外支出 | 12,800.96 | 2,332,732.36 | 1,457,769.99 | 1,156,567.63 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 59,604,092.87 | 97,783,765.64 | 124,210,778.64 | 100,077,529.62 |
| 减:所得税费用 | 7,821,503.23 | 13,461,738.66 | 11,145,338.59 | 9,480,553.15 |
| 六、净利润 | 51,782,589.64 | 84,322,026.98 | 113,065,440.05 | 90,596,976.47 |
| 持续经营净利润 | 51,782,589.64 | 84,322,026.98 | 113,065,440.05 | 90,596,976.47 |
| 归属于母公司股东的净利润 | 51,116,537.85 | 100,200,680.03 | 113,761,436.1 | 91,020,627.53 |
| 少数股东损益 | 666,051.79 | -15,878,653.05 | -695,996.05 | -423,651.06 |
| (一)基本每股收益 | 0.07 | 0.13 | 0.15 | 0.12 |
| (二)稀释每股收益 | 0.07 | 0.13 | 0.15 | 0.12 |
| 八、其他综合收益 | -842,776.01 | 7,829,841.42 | -6,794,267.1 | 997,864.75 |
| 归属于母公司股东的其他综合收益 | -716,359.61 | 6,655,365.21 | -5,775,127.04 | 848,185.04 |
| 九、综合收益总额 | 50,939,813.63 | 92,151,868.4 | 106,271,172.95 | 91,594,841.22 |
| 归属于母公司股东的综合收益总额 | 50,400,178.24 | 106,856,045.24 | 107,986,309.06 | 91,868,812.57 |
| 归属于少数股东的综合收益总额 | 539,635.39 | -14,704,176.84 | -1,715,136.11 | -273,971.35 |
| 公告日期 | 2025-04-26 | 2025-04-26 | 2024-10-28 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |